Wei Wei, Cao Yongfu, Lu Xin, Wang Long, Li Jianbin, Deng Guojun, Li Donghai, Xiao Limin
Department of Neurosurgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17 Yongwai Street, Nanchang, 330006, Jiangxi, China.
Department of Neurosurgery, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong High Education Institutes, The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Sci Rep. 2025 Jan 5;15(1):854. doi: 10.1038/s41598-024-84719-z.
The role of RBM47, an RNA-binding protein, in shaping the immune landscape of gliomas and tumor immune responses is yet to be fully studied. Therefore, a comprehensive investigation into the immunomodulatory roles of RBM47 in gliomas was conducted, leveraging gene expression data from multi-omic datasets. The prognosis of patients with gliomas considering RBM47 was elucidated using bioinformatics methods and clinical data, with results validated using immunohistochemistry and immunofluorescence analyses. The expression of RBM47 in gliomas was higher than that in normal tissues and was positively correlated with the World Health Organization tumor grade. Increased RBM47 expression is associated with poor prognosis in patients with glioma, serving as an independent predictor of overall survival. The nomogram combining RBM47 expression levels with clinical prognostic factors demonstrated strong predictive accuracy, achieving a C-index of up to 0.863 in both TCGA training and CGGA validation groups. Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and Gene Set Variation Analysis indicated that RBM47 is closely related to immunity and inflammation. Single-cell sequencing and immunofluorescence assays confirmed the enrichment of RBM47 in CD163 + macrophages. Therefore, RBM47 plays a vital role in the immune microenvironment of gliomas and may be a potential immunotherapy target.
RNA结合蛋白RBM47在塑造胶质瘤免疫格局和肿瘤免疫反应中的作用尚未得到充分研究。因此，利用多组学数据集的基因表达数据，对RBM47在胶质瘤中的免疫调节作用进行了全面研究。使用生物信息学方法和临床数据阐明了考虑RBM47的胶质瘤患者的预后，并通过免疫组织化学和免疫荧光分析验证了结果。RBM47在胶质瘤中的表达高于正常组织，且与世界卫生组织肿瘤分级呈正相关。RBM47表达增加与胶质瘤患者的不良预后相关，是总生存期的独立预测因子。将RBM47表达水平与临床预后因素相结合的列线图显示出强大的预测准确性，在TCGA训练组和CGGA验证组中的C指数均高达0.863。基因本体论、京都基因与基因组百科全书和基因集变异分析表明，RBM47与免疫和炎症密切相关。单细胞测序和免疫荧光分析证实RBM47在CD163 +巨噬细胞中富集。因此，RBM47在胶质瘤免疫微环境中起着至关重要的作用，可能是潜在的免疫治疗靶点。
